|1.||Yeo, Jane: 3 articles (08/2006 - 01/2004)|
|2.||Prous, J R: 3 articles (04/2006 - 01/2003)|
|3.||Rabasseda, X: 3 articles (04/2006 - 01/2003)|
|4.||Weimer, L E: 2 articles (12/2014 - 12/2012)|
|5.||Fragola, V: 2 articles (12/2014 - 12/2012)|
|6.||Manfredi, R: 2 articles (12/2012 - 08/2008)|
|7.||Moral, M A: 2 articles (11/2009 - 05/2009)|
|8.||Tomillero, A: 2 articles (11/2009 - 05/2009)|
|9.||Rabaud, Christian: 2 articles (11/2008 - 01/2007)|
|10.||Pavel, Simona: 2 articles (11/2008 - 01/2007)|
02/01/2007 - "Once-daily (QD) fosamprenavir (FPV) at 1,400 mg boosted with low-dose ritonavir (RTV) at 200 mg is effective when it is used in combination regimens for the initial treatment of human immunodeficiency virus infection. "
05/01/2006 - "Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study."
06/01/2007 - "Fosamprenavir is a protease inhibitor (PI) approved for the treatment of HIV-1 infection. "
07/01/2006 - "Fosamprenavir is a protease inhibitor (PI) prodrug used for the treatment of HIV-1 infection. "
08/01/2008 - "Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection."
02/01/2009 - "In drug-naïve subjects, regimens based on ATV/r have shown non-inferiority compared to lopinavir (LPV)/r (CASTLE study) or fosamprenavir/r (ALERT trial), generally with improved tolerance (less diarrhea and dyslipidemia). "
01/01/2009 - "Overall, lopinavir/ritonavir and fosamprenavir/ritonavir tend to show the highest rates of drug-related grade 2-4 diarrhea, compared with atazanavir/ritonavir, darunavir/ritonavir, or saquinavir/ritonavir. "
|4.||HIV Infections (HIV Infection)
01/01/2004 - "In conclusion, fosamprenavir appears to be a promising agent for the treatment of antiretroviral therapy-naive patients with HIV infection."
01/01/2004 - "In conclusion, fosamprenavir-based regimens have shown good antiviral efficacy and are generally well tolerated in antiretroviral therapy-naive patients with HIV infection. "
01/01/2004 - "Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection."
08/01/2002 - "The possibility of a lower pill burden offered by GW433908 may be of clinical benefit in the treatment of HIV infection."
12/01/2008 - "Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients."
|4.||Protease Inhibitors (Protease Inhibitor)
|5.||lamivudine drug combination abacavir
|3.||Highly Active Antiretroviral Therapy (HAART)